ISSUE #22
Feb 4, 2026
📚
Browse Past Issues
Editor's Note
🎬 Our New YouTube Channel is live!
We'll be diving into Korea's Biotech Industry in English.
▶
Follow us now and ride the wave
🌊
▶ Notice
▶ Recent Events
▶ Latest News
What's Coming Up?
Experience the Ultimate Global Biotech Opportunities in
Seoul
!
EAST-WEST BIOPHARMA SUMMIT: SEOUL 2026
March 9-11, 2026
Top Stories
KoreaBIO Recruiting Trainees for Bio Professional Workforce Development GMP Program
This training program is jointly operated by the KoreaBIO and six regional bio centers, including the Jeonnam Bio Foundation.
Feb 4, 2026
· via
[The Asia Business Daily]
Samsung Bioepis cleared for eye treatment biosimilar sales in Europe, UK
Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.
Jan 30, 2026
· via [The Korea Times]
Korea's Hanmi Pharma secures export deal with Mexican partner Sanfer for GLP-1 obesity drug and more
Samsung Bioepis has reached a settlement with Regeneron and Bayer over the commercialization of SB15, a biosimilar to eye treatment Eylea, allowing the Korean drug developer to launch the treatment in Europe and the United Kingdom.
Jan 28, 2026
· via [BioSpectrum Asia]
Inside Korea Bio
Here's what's happening across Korea's bio industry!
🚀 Korea Goes Global
∎ "No.1 in the U.S., Six Approvals in Europe"...
K-Biosimilars
Sweep the Two Major Markets
- The Asia Business Daily
∎ Korea's Medipost,
success story
of tech-focused private equity firms Crescendo, Skylake - KED Global
∎ Korea's SK bioscience
in-licenses RSV preventive mAb
candidate
from Gates Medical Research Institute - BioSpectrum Asia
∎ Celltrion
secures Canadian approval
for high-dose OMLYCLO 300mg PFS and autoinjector formulations - THE BIO
∎ Dewcell demonstrates
world’s first
50-liter bioreactor production of
artificial platelets
- THE BIO
∎ Domestic Market Saturation' Drives
K-Botox to Scale Up
in Emerging Markets - The Asia Business Daily
∎ Dong-A ST
secures Canadian approval
for Stelara biosimilar ‘Imuldosa’ - THE BIO
∎ UAE
Grants MFDS
Reference Status, Opening Arab Markets - HITNEWS
∎
K-Beauty Exports Jump 34%
in January Amid
Global Expansion - Business Korea
∎ Noul to
Supply AI
Cervical Cancer Diagnostic Solution
to Mexico
- Business Korea
∎ Rokit Healthcare
targets global
diabetes and dementia markets
with AI anti-aging
launch - KBR
∎ Dabeeo
partners with Indonesia
’s Triputra to deploy
AI plantation
monitoring system - The Korea Herald
📈 Growth & Performance
∎ Celltrion’s Herzuma
Cuts Breast Cancer Treatment Time
- Business Korea
∎ Dx&Vx
files patent
for self-assembly nanoparticle technology for
NGS
- KBR
∎ GC Biopharma
starts human testing
of Covid-19 mRNA vaccine GC4006A - KBR
∎ GI Innovation launches
global randomized phase 2 trial
of GI-101A, a key step toward commercialization of efdelikofusp alfa - THE BIO
∎ Huons
Signs Distribution Agreement
with Rappeler for Vitamin C and G6PD Diagnostic Devices - Pharm EDaily
∎ Keytruda Reimbursement
Expansion to Ease Burden
in Underserved Cancers - HITNEWS
∎ South Korea launches
AI platform to
transform agriculture and boost exports
- Chosun Biz
∎ Hyundai Steel mass
produces low-carbon steel
using world's first hybrid process - The Korea Herald
∎ Korea expands patent
fast-track to
physical AI
and cuts wait times - Chosun Biz
∎
AI precisely predicts
optimal kimchi ripeness through chemical analysis - DongA Science
📰
Join our press list
Get KoreaBIO updates
& media resources
💬
Share Your thoughts!
How was your letter today?
✉️
Korean Newsletter
Daily biotech news from Korea and around the world
— in Korean
Stay connected with
everything
KoreaBIO
Watch and Join!
Explore More
KoreaBIO (Korea Biotechnology Industry Organization)
700 Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
+82-31-628-0037
수신거부
Unsubscribe
